Dual-Phase Emulsion for Stable Antigen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunogenic compositions face challenges in enhancing immune responses, stability during storage, and ease of preparation, particularly in co-administering vectorized antigens and immunostimulating agents, with issues related to antigen leakage and particle size affecting their efficacy.
Innovation Solution
An immunogenic composition comprising a continuous aqueous phase and two dispersed phases of droplets, where one phase contains an antigen covalently linked to surfactant-carrying droplets and the other phase includes an immunostimulating agent, specifically designed to enhance immune responses and stability, with controlled particle size for improved cellular capture.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antigens are co-administered with immunostimulating agents to enhance immunogenicity, then immune response is improved, but preparation complexity and stability control become more difficult
Solution Approach 1:
The invention divides the immunogenic composition into two distinct dispersed phases: phase 1 containing the antigen vectorized on surfactant-carrying droplets, and phase 2 containing the immunostimulating agent in separate droplets. This segmentation allows each component to be optimized independently while maintaining stability and enhancing immune response when co-administered.
Solution Approach 2:
The invention creates a composite emulsion system combining lipid-based droplets carrying antigens with separate droplets carrying immunostimulating agents. This composite structure integrates multiple functional components (amphiphilic lipids, solubilizing lipids, co-surfactants, and immunostimulating agents) into a single stable formulation that enhances immunogenicity while controlling preparation complexity.
2Reliability
If polymeric nanoparticles are used to vectorize antigens, then immune response is enhanced, but antigen leakage occurs and storage stability is reduced
Solution Approach 1:
The invention changes the material parameter from polymeric nanoparticles to lipid-based droplets with specific surfactant compositions. This parameter change maintains the ability to vectorize antigens and enhance immune response while significantly improving storage stability and preventing antigen leakage, as lipids provide a more stable matrix for antigen encapsulation.
Solution Approach 2:
The invention uses surfactant-carrying lipid droplets that form flexible yet stable interfaces around the antigen. The surfactant layer acts as a protective thin film that prevents antigen leakage while allowing controlled interaction with immune cells, thereby maintaining storage stability without compromising immune response enhancement.
3Reliability
If particle size is reduced to improve cellular capture, then immune response is enhanced, but manufacturing precision requirements increase
Solution Approach 1:
The invention employs dynamic emulsification processes that allow controlled formation of droplets with optimized size distribution. The use of amphiphilic lipids and co-surfactants creates dynamic interfaces that facilitate uniform droplet formation at optimal sizes for cellular capture, balancing manufacturing feasibility with immune response enhancement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly amplifies immune responses, is stable during storage, and can be easily prepared for industrial use, facilitating the production of antibodies and vaccines by effectively targeting immune cells.
Implementation Method 1
An immunogenic composition in the form of an emulsion comprising a continuous aqueous phase, a first lipid phase dispersed in the form of droplets and comprising an antigen covalently linked to said droplets, and a second dispersed phase comprising an immunostimulating agent
Implementation Method 2
a first lipid phase dispersed in the form of droplets and comprising an antigen covalently linked to said droplets
Data Source
Figure 1~3
Figure 4~5
Figure 6~7
AI summary
The application relates to an immunogenic composition comprising a continuous aqueous phase and at least two dispersed phases 1 and 2 in the form of droplets, wherein the dispersed phase 1 comprises a surfactant 1 carrying an antigen and the dispersed phase 2 comprises an immunostimulating agent 2, to the process for preparing the same and to the uses thereof, in particular for preparing antibodies, as a medicament, or a vaccine, or in an immunization method.